[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR091272A1 - Pirazolopirimidona y pirazolopiridona como inhibidores de tanquirasa - Google Patents

Pirazolopirimidona y pirazolopiridona como inhibidores de tanquirasa

Info

Publication number
AR091272A1
AR091272A1 ARP130101979A AR091272A1 AR 091272 A1 AR091272 A1 AR 091272A1 AR P130101979 A ARP130101979 A AR P130101979A AR 091272 A1 AR091272 A1 AR 091272A1
Authority
AR
Argentina
Prior art keywords
alkyl
hydrogen
cycloalkyl
group
hydroxyalkyl
Prior art date
Application number
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR091272A1 publication Critical patent/AR091272A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Los compuestos de fórmula (1) resultan útiles en el tratamiento del cáncer. Reivindicación 1: Compuesto de la fórmula (1) en la que: Q y X son, independientemente en cada aparición, N o CH; R¹ se selecciona de entre el grupo que consiste de hidrógeno, alquilo C₁₋₆, hidroxialquilo C₁₋₆, dihidroxi-alquilo C₁₋₆, 1,1-dioxotián-4-ilo o tetrahidropirán-4-ilo; R² es un resto de fórmula (2) ó (3); Y se selecciona de entre el grupo que consiste de CR⁴R⁵ o NR⁴, en el que R⁵ es hidrógeno, alquilo C₁₋₆, -OH o -CN; R³ se selecciona de entre el grupo que consiste de: (i) hidrógeno, (ii) alquilo C₁₋₆, (iii) haloalquilo C₁₋₆, (iv) halógeno, (v) alcoxi C₁₋₆, (vi) S(O)₂R³ᵃ en la que R³ᵃ es alquilo C₁₋₆, cicloalquilo C₃₋₆, alquil C₁₋₃-cicloalquilo C₃₋₆ o NH₂ o (vii) CONR³ᵇR³ᶜ en la que R³ᵇ y R³ᶜ son independientemente hidrógeno, alquilo C₁₋₃ o R³ᵇ y R³ᶜ conjuntamente con el nitrógeno al que se encuentran unidos forman una amina cíclica; R⁴ se selecciona de entre el grupo que consiste de: (i) hidrógeno, (ii) alquilo C₁₋₆, (iii) haloalquilo C₁₋₆ sustituido opcionalmente con hidroxilo, (iv) cicloalquilo C₃₋₇, (v) cicloalquil C₃₋₇-alquilo C₁₋₃, (vi) bicicloalquilo C₅₋₁₀, (vii) el resto de formula (4) en la que R⁶ se selecciona independientemente de entre el grupo que consiste de: (a) alquilo C₁₋₆, (b) haloalquilo C₁₋₆ sustituido opcionalmente con hidroxilo, (c) hidroxialquilo C₁₋₆, (d) dihidroxi-alquilo C₁₋₆, (e) alcoxi C₁₋₃-alquilo C₁₋₃, (f) cicloalquilo C₃₋₇, (g) acilo C₁₋₆, (h) halo, (i) ciano, (j) NO₂, (k) carboxilo, (l) alcoxicarbonilo C₁₋₆, (m) CONR⁴ᵇR⁴ᶜ en la que R⁴ᵇ y R⁴ᶜ son independientemente hidrógeno, alquilo C₁₋₆ o R⁴ᵇ y R⁴ᶜ conjuntamente con el átomo de nitrógeno al que se encuentran unidos forman una amina cíclica, (n) -S(O)₂R⁴ᵃ en la que R⁴ᵃ es alquilo C₁₋₆, cicloalquilo C₃₋₆, alquil C₁₋₃-cicloalquilo C₃₋₆ o NH₂, (o) NR⁴ᵇR⁴ᶜ, en la que R⁴ᵇ y R⁴ᶜ son independientemente alquilo C₁₋₆ o hidrógeno, (p) OR⁴ᵈ en la que R⁴ᵈ se selecciona de entre el grupo que consiste de: (i) hidrógeno, (ii) alquilo C₁₋₆, (iii) alcoxi C₁₋₃-alquilo C₁₋₃, (iv) hidroxialquilo C₁₋₆, sustituyendo además opcionalmente dicho hidroxialquilo con halógeno, (v) dihidroxi-alquilo C₁₋₆, (vi) (alquilén)₂₋₆NR⁴ᵉCR⁴ᶠ en la que R⁴ᵉ y R⁴ᶠ son independientemente hidrógeno o alquilo C₁₋₆ o R⁴ᵉ y R⁴ᶠ conjuntamente con el nitrógeno al que se encuentran unidos forman una amina cíclica que contiene opcionalmente otro heteroátomo seleccionado de entre NR⁴ᵍ, O ó S(O)₀₋₂ en la que R⁴ᵍ es hidrógeno o alquilo C₁₋₃, (vii) oxetanilo, (viii) tetrahidropiranilo, (ix) 1,1-dioxotianilo, (x) (1-oxotietán-3-il)metilo y (xi) (alquilén)₂₋₆OR⁴ʰ en la que R⁴ʰ es C(O)CH(NH₂)R⁴ⁱ en la que R⁴ⁱ es alquilo C₁₋₆ o P(=O)(OH)₂, (q) heterociclil-alquilo C₁₋₃ en el que dicho heterociclo es piperidina, morfolina, piperazina o 4-metilpiperazina; r) 1H-tetrazol-5-ilo, y (s) 1,1-dioxotiolán-3-ilo, (viii) heteroarilo, (ix) heteroaril-alquilo C₁₋₃, (x) heterociclilo, (xi) heterociclil-alquilo C₁₋₃, (xii) -S(O)₂R⁴ᵃ en la que R⁴ᵃ es alquilo C₁₋₆, cicloalquilo C₃₋₆, alquil C₁₋₃-cicloalquilo C₃₋₆ o NH₂, (xiii) 1,1-dioxotiolán-3-ilo; en el que: cada uno de dichos cicloalquilos se sustituye opcionalmente con uno a tres hidroxilos o alcoxi C₁₋₃-alcoxi C₁₋₆; cada uno de dichos heteroarilos opcionalmente se sustituye adicionalmente con alquilo C₁₋₆, alcoxi C₁₋₆, hidroxialquilo C₁₋₃, haloalquilo C₁₋₆, halógeno, CN, pirazinilo o alquilsulfonilo C₁₋₆; cada uno de dichos heterociclos se selecciona de entre tetrahidropirán-4-ilo, tetrahidrofurán-2-ilo, oxetán-3-ilo, 1,1-dioxo-tetrahidrotiofenilo, 1,1-dioxotiolán-3-ilo, 1-Boc-piperidinilo, piperidin-4-ilo, 1-metil-piperidin-4-ilo, 1 -Boc-piperazin-4-ilo, 1-metil-piperazin-4-ilo o piperazin-4-ilo; o una sal farmacéuticamente aceptable de los mismos.
ARP130101979 2012-06-07 2013-06-05 Pirazolopirimidona y pirazolopiridona como inhibidores de tanquirasa AR091272A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261656644P 2012-06-07 2012-06-07

Publications (1)

Publication Number Publication Date
AR091272A1 true AR091272A1 (es) 2015-01-21

Family

ID=48570150

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130101979 AR091272A1 (es) 2012-06-07 2013-06-05 Pirazolopirimidona y pirazolopiridona como inhibidores de tanquirasa

Country Status (12)

Country Link
US (1) US20130345215A1 (es)
EP (1) EP2858994A1 (es)
JP (1) JP2015518870A (es)
KR (1) KR20150016406A (es)
CN (1) CN104540830A (es)
AR (1) AR091272A1 (es)
BR (1) BR112014030410A2 (es)
CA (1) CA2874546A1 (es)
MX (1) MX2014014582A (es)
RU (1) RU2014151009A (es)
TW (1) TW201402570A (es)
WO (1) WO2013182546A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2822656T3 (en) 2012-03-07 2017-01-30 Inst Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
CN104350056A (zh) * 2012-06-07 2015-02-11 霍夫曼-拉罗奇有限公司 端锚聚合酶的吡咯并嘧啶酮和吡咯并吡啶酮抑制剂
EP2864330A1 (en) * 2012-06-20 2015-04-29 F. Hoffmann-La Roche AG Pyrrolopyrazone inhibitors of tankyrase
JP6456392B2 (ja) 2013-09-11 2019-01-23 インスティチュート オブ キャンサー リサーチ：ロイヤル キャンサー ホスピタル ３−アリール−５−置換イソキノリン−１−オン化合物及びその治療的使用
US10093646B2 (en) 2014-01-17 2018-10-09 Novartis Ag 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
WO2015107494A1 (en) 2014-01-17 2015-07-23 Novartis Ag 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
JP6535022B2 (ja) 2014-03-19 2019-06-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ヘテロアリールｓｙｋ阻害剤
UY36060A (es) 2014-04-02 2015-10-30 Bayer Pharma AG Compuestos de azol sustituidos con amida
KR20160007347A (ko) 2014-07-11 2016-01-20 에스티팜 주식회사 신규한 이미다조트리아지논 또는 이미다조피라지논 유도체, 및 이들의 용도
WO2016006975A2 (en) * 2014-07-11 2016-01-14 St Pharm Co., Ltd. Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
KR101739003B1 (ko) * 2014-07-11 2017-05-23 에스티팜 주식회사 신규한 트리아졸로피리미디논 또는 트리아졸로피리디논 유도체, 및 이들의 용도
WO2016006974A2 (en) * 2014-07-11 2016-01-14 St Pharm Co., Ltd. Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
WO2016203404A1 (en) * 2015-06-19 2016-12-22 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
CN107787323B (zh) 2015-06-19 2020-09-01 诺华股份有限公司 用于抑制shp2活性的化合物和组合物
CN112625028B (zh) 2015-06-19 2024-10-29 诺华股份有限公司 用于抑制shp2活性的化合物和组合物
WO2017042100A1 (en) 2015-09-11 2017-03-16 Boehringer Ingelheim International Gmbh Pyrazolyl-substituted heteroaryls and their use as medicaments
WO2017055316A1 (en) 2015-10-01 2017-04-06 Bayer Pharma Aktiengesellschaft Amido-substituted azole compounds
WO2017055313A1 (en) 2015-10-01 2017-04-06 Bayer Pharma Aktiengesellschaft Amido-substituted azole compounds
KR101777475B1 (ko) * 2015-12-08 2017-09-11 에스티팜 주식회사 신규한 디히드로피라노피리미디논 유도체 및 이들의 용도
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
CN107286169B (zh) * 2016-04-05 2020-11-24 北京四环制药有限公司 端锚聚合酶抑制剂
KR102457146B1 (ko) 2016-06-14 2022-10-19 노파르티스 아게 Shp2의 활성을 억제하기 위한 화합물 및 조성물
AU2017288755B9 (en) * 2016-06-30 2021-08-19 Japanese Foundation For Cancer Research Novel compound or pharmaceutically acceptable salt thereof
WO2018078005A1 (en) 2016-10-29 2018-05-03 Bayer Pharma Aktiengesellschaft Amido-substituted azaspiro derivatives as tankyrase inhibitors
WO2018078009A1 (en) 2016-10-29 2018-05-03 Bayer Pharma Aktiengesellschaft Amido-substituted cyclohexane derivatives
WO2018087126A1 (en) 2016-11-09 2018-05-17 Bayer Pharma Aktiengesellschaft Amido-substituted cyclohexane derivatives as inhibitors of tankyrase
ES2964956T3 (es) 2017-01-10 2024-04-10 Novartis Ag Combinación farmacéutica que comprende un inhibidor de ALK y un inhibidor de SHP2
MX2021005566A (es) 2018-11-15 2021-07-15 Nippon Shinyaku Co Ltd Compuesto de 1,3,4-oxadiazolona y farmaco.
SG11202111964UA (en) * 2019-05-02 2021-11-29 Constellation Pharmaceuticals Inc Modulators of trex1
CN112830929B (zh) * 2019-11-22 2022-09-16 江苏恒瑞医药股份有限公司 吡唑并杂芳基类化合物的制备方法
CA3225996A1 (en) * 2021-08-11 2023-02-16 Landos Biopharma, Inc. Tetrahydropyrazolopyridine-analog ligands of nlrx1 and uses thereof
KR20230072623A (ko) * 2021-11-18 2023-05-25 한국원자력의학원 탄키라제 억제용 화합물 및 이의 의학적 용도
CN118284609A (zh) * 2021-12-01 2024-07-02 St制药株式会社 用于制备三唑并嘧啶酮衍生物的方法
WO2024191139A1 (ko) * 2023-03-10 2024-09-19 에스티팜 주식회사 Kras 변이 암의 예방 또는 치료용 조성물
WO2024191138A1 (ko) * 2023-03-10 2024-09-19 에스티팜 주식회사 트리아졸로피리미디논 유도체와 mek 억제제의 병용 요법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB937725A (en) * 1960-05-11 1963-09-25 Ciba Ltd Pyrazolo[3:4-d]pyrimidines
US3720674A (en) * 1970-09-02 1973-03-13 Squibb & Sons Inc 4-amino-1h-pyrazolo(3,4-d)pyrimidine derivatives
CN1177963A (zh) * 1995-03-10 1998-04-01 圣诺菲药品有限公司 6－芳基吡唑并[3,4－d]嘧啶－4－酮和它们的组合物和使用方法
NZ303886A (en) * 1995-03-10 1998-11-25 Sanofi Winthrop Inc 1-cyclopentyl (or tert butyl)-6-aryl (or heteroaryl)-pyrazolo[3,4-d]pyrimidin-4-one derivatives and medicaments
US6200980B1 (en) * 1995-06-07 2001-03-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl purinone derivatives
JPWO2002094790A1 (ja) * 2001-05-23 2004-09-09 三菱ウェルファーマ株式会社 縮合ヘテロ環化合物およびその医薬用途
US20030139427A1 (en) * 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
NZ546477A (en) 2006-04-07 2009-04-30 Auckland Uniservices Ltd 4-Alkylamino-2-(heterocyclic)quinazolines and their use in cancer therapy
US20080234262A1 (en) * 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
US20100015141A1 (en) 2008-07-21 2010-01-21 Wyeth 4-phenoxy-6-aryl-1h-pyrazolo[3,4-d]pyrimidine and n-aryl-6-aryl-1h-pyrazolo[3,4-d]pyrimidin-4-amine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
RU2011116928A (ru) 2008-09-30 2012-11-20 Астразенека Аб (Se) Гетероциклические ингибиторы jак киназы
WO2010118367A2 (en) * 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines

Also Published As

Publication number Publication date
CN104540830A (zh) 2015-04-22
BR112014030410A2 (pt) 2017-06-27
MX2014014582A (es) 2015-05-11
US20130345215A1 (en) 2013-12-26
KR20150016406A (ko) 2015-02-11
RU2014151009A (ru) 2016-08-10
EP2858994A1 (en) 2015-04-15
CA2874546A1 (en) 2013-12-12
WO2013182546A1 (en) 2013-12-12
JP2015518870A (ja) 2015-07-06
TW201402570A (zh) 2014-01-16

Similar Documents

Publication Publication Date Title
AR091272A1 (es) Pirazolopirimidona y pirazolopiridona como inhibidores de tanquirasa
AR091519A1 (es) Inhibidores pirrolopirazona de tanquirasa
AR108388A2 (es) Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas
AR095311A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
AR099177A1 (es) Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
AR094314A1 (es) Inhibidores de fosfatidilinositol 3-cinasa
AR088449A1 (es) Benzilindazoles sustituidos
AR099785A1 (es) Compuestos heteroarilos y su uso como medicamentos
AR094911A1 (es) SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO ASÍ COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARÍNICO M₃
AR098136A1 (es) Compuestos de heteroarilo como inhibidores de btk y usos de los mismos
AR091271A1 (es) Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa
AR107170A1 (es) Compuestos heterocíclicos tricíclicos condesados como inhibidores de integrasa del vih
AR096235A1 (es) Arilquinazolinas
AR067327A1 (es) Derivados de piperidina / piperazina
AR094857A1 (es) Derivados de pirrolo[2,3-d]pirimidina
AR092269A1 (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR095422A1 (es) Compuestos de piperidina sustituidos y su uso como moduladores de receptores de orexina
CL2015002520A1 (es) Compuestos novedosos de pirimidina y piridina y su uso.
AR087809A1 (es) Benzo[b]tiofen-4-il-piperazino sustituidos, su uso en el tratamiento de enfermedades psicoticas y un metodo para su preparacion
AR094762A1 (es) Compuestos de hexahidropirano[3,4-d][1,3]tiazin-2-amina sustituida con heteroarilo
AR052419A1 (es) Derivados de bencimidazolil n-sustituidos,inhibidores del protooncogen c-kit
AR082914A1 (es) Heteroarilmetilamidas utiles para tratar enfermedades cardiovasculares y dislipemias, composiciones farmaceuticas que las contienen y proceso de preparacion de los mismos
AR095708A1 (es) Indazoles sustituidos con diaminoheteroarilo
AR093143A1 (es) Compuestos de 2-aminopiridina
AR097087A1 (es) Derivados de oxoquinazolinil-butanamida

Legal Events

Date Code Title Description
FB Suspension of granting procedure